Ovarian Cancer Coverage from Every Angle

Immunochemotherapy Primed With Oncolytic Vaccinia Virus in Platinum-Resistant Ovarian Cancer

By: Joshua Swore
Posted: Wednesday, October 21, 2020

An intraperitoneal oncolytic vaccinia virus, followed by the immunochemotherapy regimen of an intravenous carboplatin doublet with or without bevacizumab, may provide patients with platinum-resistant ovarian cancer an alternative treatment that may reverse platinum resistance. The study, which was presented as a plenary abstract at the 2020 International Gynecologic Cancer Society (IGCS) Annual Global Meeting (Abstract 1308), was conducted by Robert Holloway, MD, of AdventHealth Cancer Institute, Orlando, Florida, and colleagues.

“Virus-induced changes in the tumor microenvironment may explain the apparent clinical reversal of platinum resistance,” the investigators concluded.

The study enrolled 27 patients with platinum-resistant or -refractory ovarian cancer. Patients had a median of four prior treatments, with 52% of patients having platinum-refractory disease and 48% having platinum-resistant disease. After disease progression from recent therapies, patients received 2 days of intraperitoneal oncolytic vaccinia virus, which was followed by a carboplatin doublet with or without bevicizumab. Patients were then maintained with single-agent therapies with or without bevicizumab. Lastly, the researchers acquired biopsies of tumors before and after and virotherapy.

The investigators reported an overall response rate of 54% (95% confidence interval [CI] = 33%–74%), with 2 patients achieving a complete response; 11, a partial response; and 8, stable disease. Progression-free survival was found to be 11 months (95% CI = 6.7–13.0 months), with a 6-month progression-free survival rate of 77%. The CA-125 overall response rate was 85% (95% CI = 65%–96%). A total of 24 patients exhibited preserved or improved status while on the carboplatin doublet with or without bevacizumab. The researchers revealed a post-virotherapy increase of intratumoral infiltration of CD8-positive T cells. This finding was combined with upregulation of STAT1 expression. The authors noted that no patients reported grade 4 adverse events from virotherapy.

Disclosure: No disclosure information for study authors was provided.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.